Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PARIS and NEW YORK, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet...
-
ATLANTA, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Sharecare, the digital health company helping people manage all their health in one place, today announced it has formed a multi-faceted partnership...
-
Matthews, NC, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Carolina’s Home Medical Equipment, Inc. (www.chmei.com), a leading provider of durable medical equipment, gained national recognition on Tuesday. ...
-
BOSTON, Sept. 22, 2016 (GLOBE NEWSWIRE) -- The National Patient Safety Foundation (NPSF), an independent, not-for-profit organization that has served as a central voice for patient safety since 1997,...
-
TORONTO, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSXV:PRN) (“Profound” or the “Company”) a medical device company focused on prostate care, today announced that the first...
-
WIXOM, Mich., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney...
-
SAN JOSE, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Vocera Communications, Inc. (NYSE:VCRA), the leading healthcare communications company, today announced that long-time customer MedStar...
-
CRANBURY, N.J., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced...
-
CAMBRIDGE, Mass., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ:PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by...
-
EWING, N.J., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced safety results from the dose-blinded, multiple-dose, concentration-controlled, 26-week phase 3...